Normal view MARC view ISBD view

Yadav, Arti

Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. [electronic resource] - Molecular cancer therapeutics Jul 2011 - 1241-51 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

ISSN: 1538-8514

Standard No.: 10.1158/1535-7163.MCT-11-0004 doi

Subjects--Topical Terms:
Animals
Antineoplastic Agents--pharmacology
Benzenesulfonates--pharmacology
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Cells, Cultured
DNA-Binding Proteins--genetics
Dose-Response Relationship, Drug
Down-Regulation--drug effects
Endonucleases--genetics
Endothelial Cells--drug effects
Gene Expression Regulation, Neoplastic--drug effects
Humans
Mice
Mice, SCID
Neoplasms--drug therapy
Neoplastic Stem Cells--drug effects
Neovascularization, Pathologic--drug therapy
Niacinamide--analogs & derivatives
Phenylurea Compounds
Pyridines--pharmacology
Radiation Tolerance--drug effects
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Sorafenib
Tumor Burden--drug effects
X-ray Repair Cross Complementing Protein 1
Xenograft Model Antitumor Assays